Chi Sheng Pharma & Biotech Co., Ltd (TPEX:4111)
Taiwan · Delayed Price · Currency is TWD 30.00
+0.10 (0.33%)
May 29, 2026, 1:24 PM CST
TPEX:4111 Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,414 | 1,376 | 1,165 | 1,061 | 1,143 | 1,022 | |
Revenue Growth (YoY) | 16.08% | 18.11% | 9.86% | -7.19% | 11.81% | 4.38% |
Cost of Revenue | 845.39 | 832.82 | 768.25 | 717.76 | 720.57 | 665.72 |
Gross Profit | 568.24 | 543.66 | 397.18 | 343.1 | 422.51 | 356.58 |
Selling, General & Admin | 336.67 | 327.84 | 280.24 | 260.22 | 248.99 | 218.59 |
Research & Development | 17.7 | 16.51 | 18 | 21.67 | 19.69 | 18.94 |
Operating Expenses | 354.37 | 344.36 | 298.25 | 281.89 | 268.67 | 237.52 |
Operating Income | 213.88 | 199.3 | 98.93 | 61.21 | 153.84 | 119.06 |
Interest Expense | -0.49 | -0.52 | -1.74 | -1.46 | -1.53 | -1.09 |
Interest & Investment Income | 8.19 | 8.42 | 14.58 | 16.64 | 3 | 0.6 |
Currency Exchange Gain (Loss) | - | - | 17.08 | -0.43 | 4.72 | -1.76 |
Other Non Operating Income (Expenses) | 4.47 | -0.4 | 11.22 | 11.5 | 7.21 | 8.06 |
EBT Excluding Unusual Items | 226.04 | 206.8 | 140.08 | 87.46 | 167.24 | 124.86 |
Gain (Loss) on Sale of Investments | - | - | - | - | -5.03 | - |
Gain (Loss) on Sale of Assets | - | - | -2.38 | -0.13 | 0.07 | 0.12 |
Asset Writedown | - | - | - | - | - | 6.8 |
Other Unusual Items | - | - | - | 0 | - | - |
Pretax Income | 226.04 | 206.8 | 137.7 | 87.33 | 162.28 | 131.78 |
Income Tax Expense | 46.62 | 42.52 | 27.07 | 18.66 | -17 | 24.08 |
Earnings From Continuing Operations | 179.42 | 164.28 | 110.63 | 68.67 | 179.28 | 107.7 |
Earnings From Discontinued Operations | - | - | - | - | -25.28 | -26.95 |
Net Income | 179.42 | 164.28 | 110.63 | 68.67 | 154.01 | 80.75 |
Net Income to Common | 179.42 | 164.28 | 110.63 | 68.67 | 154.01 | 80.75 |
Net Income Growth | 42.10% | 48.49% | 61.10% | -55.41% | 90.72% | 36.54% |
Shares Outstanding (Basic) | - | 60 | 60 | 60 | 60 | 60 |
Shares Outstanding (Diluted) | - | 60 | 60 | 60 | 60 | 60 |
Shares Change (YoY) | - | 0.40% | 0.12% | -0.16% | 0.06% | 0.10% |
EPS (Basic) | - | 2.75 | 1.85 | 1.15 | 2.57 | 1.35 |
EPS (Diluted) | - | 2.72 | 1.84 | 1.14 | 2.56 | 1.34 |
EPS Growth | - | 47.98% | 60.83% | -55.37% | 90.77% | 36.85% |
Free Cash Flow | 170.87 | 180.75 | 129.01 | -26.98 | 109.53 | -125.53 |
Free Cash Flow Per Share | - | 2.99 | 2.15 | -0.45 | 1.82 | -2.09 |
Dividend Per Share | - | - | 0.952 | 0.952 | 1.143 | 0.952 |
Dividend Growth | - | - | - | -16.67% | 20.00% | - |
Gross Margin | 40.20% | 39.50% | 34.08% | 32.34% | 36.96% | 34.88% |
Operating Margin | 15.13% | 14.48% | 8.49% | 5.77% | 13.46% | 11.65% |
Profit Margin | 12.69% | 11.94% | 9.49% | 6.47% | 13.47% | 7.90% |
Free Cash Flow Margin | 12.09% | 13.13% | 11.07% | -2.54% | 9.58% | -12.28% |
EBITDA | 287.61 | 273.56 | 165.23 | 123.17 | 219.2 | 190.95 |
EBITDA Margin | 20.34% | 19.87% | 14.18% | 11.61% | 19.18% | 18.68% |
D&A For EBITDA | 73.73 | 74.25 | 66.3 | 61.96 | 65.36 | 71.9 |
EBIT | 213.88 | 199.3 | 98.93 | 61.21 | 153.84 | 119.06 |
EBIT Margin | 15.13% | 14.48% | 8.49% | 5.77% | 13.46% | 11.65% |
Effective Tax Rate | 20.63% | 20.56% | 19.66% | 21.36% | - | 18.27% |
Revenue as Reported | 1,414 | 1,376 | - | - | - | - |